UX-GIP001
Phase 1Biologic
UX-GIP001 is one of 50 biologic programs targeting Epilepsy. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
84 competitors in Epilepsy
#DrugCompanyPhaseTrials
1Vimpat
UCBApproved
Tegretol
NovartisApproved
Trileptal
NovartisApproved
Fycompa
CCatalyst Biosciences
Approved
Diamox
TevaApproved
Briviact
UCBPhase 3
Dilantin
VViatris Specialty LLC
Approved
Zoloft
VViatris Specialty LLC
Approved
Ketalar
AAultman Health Foundation
Approved
Glucophage
EMD SeronoApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Temporal Lobe Epilepsy1 trial
Exploratory Study of UX-GIP001 Cell Therapy in Adult Patients With Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT07244328·6 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for UX-GIP001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details